الفهرس | Only 14 pages are availabe for public view |
Abstract Introduction: Breast cancer is the most commonly diagnosed cancer in females constituting 11.7% of total cancer cases, about 2,261,419 new cases of breast cancer were diagnosed in 2020 worldwide patients with locally advanced breast cancer, and some with earlier-stage disease (particularly if triple negative or human epidermal growth factor receptor 2 [HER2] positive), are treated with neoadjuvant systemic therapy. The goal of neoadjuvant chemotherapy is to induce a tumor response before surgery and enable breast conservation, assess responsiveness of the tumor to chemotherapy and achieving pCR which correlate with improved survival. Aim of the Work: Describe the relation between the body mass index and response to neoadjuvant chemotherapy in breast cancer patients regarding achieving pCR or less than pCR. Patients and Methods: This is a retrospective study that included all female patients with pathologically proven locally advanced non metastatic breast cancer who received neoadjuvant chemotherapy at the medical oncology department, NCI, Cairo University in the period between January 2018 till January 2019. Results: Our study included 167 patients .The Median weight of the cases was 80 kg. Median BMI was 33.5 with range between 20.7 and 54.2.Median age was 46 years old, 67.6% were premenopausal, positive family history was found in 18% of cases, about 44.9% of the patients were luminal A, 20.9% were TPBS, 23.3% were TNBC and 10.7% were HER2 enriched. About 26.3% of the patients achieved pCR 88.6% of them were overweight and obese. The relation between BMI and MIILER grade was insignificant. Conclusion: Our study didn’t show a relation between the body mass index and response to neoadjuvant chemotherapy. |